Rapid Detection of Antimicrobial Resistance Genes in Critically Ill Children Using a Custom TaqMan Array Card
- PMID: 38136735
- PMCID: PMC10740637
- DOI: 10.3390/antibiotics12121701
Rapid Detection of Antimicrobial Resistance Genes in Critically Ill Children Using a Custom TaqMan Array Card
Abstract
Bacteria are identified in only 22% of critically ill children with respiratory infections treated with antimicrobial therapy. Once an organism is isolated, antimicrobial susceptibility results (phenotypic testing) can take another day. A rapid diagnostic test identifying antimicrobial resistance (AMR) genes could help clinicians make earlier, informed antimicrobial decisions. Here we aimed to validate a custom AMR gene TaqMan Array Card (AMR-TAC) for the first time and assess its feasibility as a screening tool in critically ill children. An AMR-TAC was developed using a combination of commercial and bespoke targets capable of detecting 23 AMR genes. This was validated using isolates with known phenotypic resistance. The card was then tested on lower respiratory tract and faecal samples obtained from mechanically ventilated children in a single-centre observational study of respiratory infection. There were 82 children with samples available, with a median age of 1.2 years. Major comorbidity was present in 29 (35%) children. A bacterial respiratory pathogen was identified in 13/82 (16%) of children, of which 4/13 (31%) had phenotypic AMR. One AMR gene was detected in 49/82 (60%), and multiple AMR genes were detected in 14/82 (17%) children. Most AMR gene detections were not associated with the identification of phenotypic AMR. AMR genes are commonly detected in samples collected from mechanically ventilated children with suspected respiratory infections. AMR-TAC may have a role as an adjunct test in selected children in whom there is a high suspicion of antimicrobial treatment failure.
Keywords: antibacterial agents; antimicrobial resistance; child; critical illness; rapid diagnostic tests; respiratory system.
Conflict of interest statement
M.D.C. is the inventor of a patent held by the Secretary of State for Health (UK government) EP2788503, which covers some of the genetic sequences used in this study. V.N. is a founder, director, and shareholder in Cambridge Infection Diagnostics (CID), a commercial company aimed at developing molecular diagnostics in infection and antimicrobial and AMR stewardship. A.C.M. and S.B. are members of the Scientific Advisory Board of CID. A.C.M. receives speaking fees from Boston Scientific. N.P. has received speaker fees from BioMérieux (Marcy-l’Étoile, France). All other authors declare no conflicts of interest.
Figures
References
-
- Clark J., White D., Daubney E., Curran M., Bousfield R., Gouliouris T., Powell E., Palmer A., Agrawal S., Inwald D., et al. Low Diagnostic Yield and Time to Diagnostic Confirmation Results in Prolonged Use of Antimicrobials in Critically Ill Children. Wellcome Open Res. 2021;6:119. doi: 10.12688/wellcomeopenres.16848.1. - DOI - PMC - PubMed
-
- Papan C., Meyer-Buehn M., Laniado G., Nicolai T., Griese M., Huebner J. Assessment of the Multiplex PCR-Based Assay Unyvero Pneumonia Application for Detection of Bacterial Pathogens and Antibiotic Resistance Genes in Children and Neonates. Infection. 2018;46:189–196. doi: 10.1007/s15010-017-1088-y. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
